Eylea 114.3 mg/ml solution for injection
22578
Approved small_molecule active
Quick answer
Eylea 114.3 mg/ml solution for injection for Neovascular age-related macular degeneration (nAMD), Diabetic macular edema (DME) is a Approved program (small_molecule) at Bayer AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bayer AG
- Indication
- Neovascular age-related macular degeneration (nAMD), Diabetic macular edema (DME)
- Phase
- Approved
- Modality
- small_molecule
- Status
- active